The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia

Por Miller, Thaddeus L, Cirule, Andra, Wilson, Fernando A, Holtz, Timothy H, Riekstina, Vija, Cain, Kevin P, Moonan, Patrick K, Leimane, Vaira
Publicado em 2013

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

Por Stagg, Helen R., White, Peter J., Riekstiņa, Vija, Cīrule, Andra, Šķenders, Ģirts, Leimane, Vaira, Kuksa, Liga, Dravniece, Gunta, Brown, James, Jackson, Charlotte
Publicado no Emerg Infect Dis (2016)

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

Por Stagg, Helen R., Brown, James, Ibraim, Elmira, Riekstiņa, Vija, Viiklepp, Piret, Cīrule, Andra, Cocei, Horia, Danilovitš, Manfred, Dravniece, Gunta, Jackson, Charlotte, White, Peter J.
Publicado no PLoS One (2015)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

Por Skripconoka, Vija, Danilovits, Manfred, Pehme, Lea, Tomson, Tarmo, Skenders, Girts, Kummik, Tiina, Cirule, Andra, Leimane, Vaira, Kurve, Anu, Levina, Klavdia, Geiter, Lawrence J., Manissero, Davide, Wells, Charles D.
Publicado em 2013

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis

Por Tupasi, Thelma, Gupta, Rajesh, Danilovits, Manfred, Cirule, Andra, Sanchez-Garavito, Epifanio, Xiao, Heping, Cabrera-Rivero, Jose L, Vargas-Vasquez, Dante E, Gao, Mengqiu, Awad, Mohamed, Gentry, Leesa M, Geiter, Lawrence J, Wells, Charles D
Publicado no Bull World Health Organ (2016)